Google DeepMind’s AlphaFold has already revolutionized scientists’ understanding of proteins. Now, the ability of the platform to design safe and effective drugs is about to be put to the test.
Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize–winning AI technology. “We’re gearing up to go into the clinic,” Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. “It’s going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.”
Jaderberg did not elaborate on the timeline, but it’s later than the company had